Skip to main content

Table 3 Cardiovascular and mortality outcomes in studies assessing aspirin in patients with diabetes for the primary prevention of major adverse cardiovascular events

From: Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis

Study and Year

Total Patients with Diabetes

MACE (ASA)

MACE (Control)

Total Mortality (ASA)

Total Mortality (Control)

CV Mortality (ASA)

CV Mortality (Control)

Total MI* (ASA)

Total MI* (Control)

Total Stroke* (ASA)

Total Stroke* (Control)

PHS, 1989

533

-

-

-

-

-

-

11

26

-

-

ETDRS, 1992

3711

333

361

340

366

244

275

241

283

92

78

HOT, 1998

1501

47

54

40

36

23

26

11

18

20

22

PPP, 2003

1031

14

20

25

20

10

8

5

10

9

10

WHS, 2005

1027

51

55

-

-

-

-

36

24

15

31

POPADAD, 2008

1276

127

132

94

101

43

35

90

82

37

50

JPAD, 2008

2539

40

46

34

38

1

10

12

14

28

32

  1. MACE: major adverse cardiovascular events, ASA: aspirin, CV: cardiovascular, MI: myocardial infarction, *: non-fatal and fatal, " - ": not reported, PHS: Physicians' Health Study, ETDRS: Early Treatment Diabetic Retinopathy Study, HOT: Hypertension Optimal Treatment, PPP: Primary Prevention Project, WHS: Women's' Health Study, POPADAD: Prevention and Progression of Arterial Disease and Diabetes Trial, JPAD: Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes.